April 10 (Reuters) - The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with "human-relevant methods," including the use of AI-based models.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.